探索物质使用与精神障碍的复杂交叉点：一项综合综述
Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review.
作者信息
Bahji Anees
机构信息
Departments of Psychiatry and Community Health Sciences & Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB T2R 1N4, Canada.
出版信息
J Clin Med. 2024 Feb 9;13(4):999. doi: 10.3390/jcm13040999.
Abstract
The co-occurrence of substance use disorders (SUDs) and psychiatric conditions, often referred to as comorbidity or concurrent disorders, presents intricate challenges in both diagnosis and treatment. This comprehensive narrative review aims to synthesize and critically evaluate the existing evidence surrounding the management of individuals with comorbid SUDs and psychiatric disorders. Comorbidity in these domains carries profound implications for clinical practice, research, and policymaking, emphasizing the need for a holistic understanding of the intricate dynamics that arise when these conditions coexist. This review explores recent research findings, evidence-based guidelines, and emerging trends within the field, offering valuable insights for clinicians, researchers, and policymakers seeking to navigate the complex terrain of comorbidity in substance use and psychiatric disorders.
摘要
物质使用障碍（SUDs）与精神疾病的共病，通常被称为共病或并发疾病，在诊断和治疗方面都带来了复杂的挑战。这篇全面的叙述性综述旨在综合并批判性地评估围绕患有共病性物质使用障碍和精神疾病个体管理的现有证据。这些领域的共病对临床实践、研究和政策制定具有深远影响，强调需要全面理解这些疾病共存时出现的复杂动态。本综述探讨了该领域的最新研究结果、循证指南和新趋势，为寻求应对物质使用和精神疾病共病复杂领域的临床医生、研究人员和政策制定者提供了宝贵的见解。
相似文献
1
Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review.
J Clin Med. 2024 Feb 9;13(4):999. doi: 10.3390/jcm13040999.
2
Socioeconomic Burden of Psychiatric Cancer Patients: A Narrative Review.
Cancers (Basel). 2024 Mar 9;16(6):1108. doi: 10.3390/cancers16061108.
3
Recovery schools for improving behavioral and academic outcomes among students in recovery from substance use disorders: a systematic review.
Campbell Syst Rev. 2018 Oct 4;14(1):1-86. doi: 10.4073/csr.2018.9. eCollection 2018.
4
Delivery Outcomes Among Pregnant Women With Comorbid Psychiatric and Substance Use Disorders Receiving Comprehensive Treatment.
J Am Psychiatr Nurses Assoc. 2024 Jan-Feb;30(1):121-131. doi: 10.1177/10783903221079384. Epub 2022 Feb 21.
5
Epidemiology of comorbid substance use and psychiatric disorders in Asia.
Curr Opin Psychiatry. 2012 May;25(3):172-80. doi: 10.1097/YCO.0b013e3283523c26.
6
Research landscape analysis on dual diagnosis of substance use and mental health disorders: key contributors, research hotspots, and emerging research topics.
Ann Gen Psychiatry. 2024 Aug 30;23(1):32. doi: 10.1186/s12991-024-00517-x.
7
Comorbidity of substance use disorders and other psychiatric disorders among adolescents: evidence from an epidemiologic survey.
Drug Alcohol Depend. 2007 Apr;88 Suppl 1(Suppl 1):S4-13. doi: 10.1016/j.drugalcdep.2006.12.010. Epub 2007 Feb 1.
8
Attention Deficit/Hyperactivity Disorder and Global Severity Profiles in Treatment-Seeking Patients with Substance Use Disorders.
Eur Addict Res. 2020;26(4-5):201-210. doi: 10.1159/000508546. Epub 2020 Jun 22.
9
Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990-2015: Systematic review and meta-analysis.
J Affect Disord. 2016 Dec;206:331-349. doi: 10.1016/j.jad.2016.07.011. Epub 2016 Jul 9.
10
A clinical approach to the assessment and management of co-morbid eating disorders and substance use disorders.
BMC Psychiatry. 2013 Nov 7;13:289. doi: 10.1186/1471-244X-13-289.
引用本文的文献
1
Comprehensive Review on Association of Bipolar Disorder and Substance Abuse: Dual Diagnosis and Treatment Approaches.
Cureus. 2025 Jun 19;17(6):e86363. doi: 10.7759/cureus.86363. eCollection 2025 Jun.
2
Exploring the Determinants of Treatment Completion Among Youth Who Received Medication-Assisted Treatment in the United States.
Healthcare (Basel). 2025 Apr 2;13(7):798. doi: 10.3390/healthcare13070798.
3
Nationwide study of emergency care quality for patients with substance use disorders and dual diagnoses across three distinct patient populations.
BMC Psychiatry. 2025 Mar 31;25(1):311. doi: 10.1186/s12888-025-06712-8.
4
Efficacy of Transcranial Direct Current Stimulation (tDCS) on Neuropsychiatric Symptoms in Substance Use Disorder (SUD)-A Review and Insights into Possible Mechanisms of Action.
J Clin Med. 2025 Feb 18;14(4):1337. doi: 10.3390/jcm14041337.
5
Evidence-based Interventions for Youth With Concurrent Mental Health and Substance Use Disorders: A Scoping Review: Interventions fondées sur des données probantes pour les jeunes atteints de troubles concomitants de santé mentale et liés à l'usage de substances psychoactives : une étude de la portée.
Can J Psychiatry. 2025 Jan 6:7067437241300957. doi: 10.1177/07067437241300957.
6
Methylphenidate abuse and misuse in patients affected with a psychiatric disorder and a substance use disorder: a systematic review.
Front Psychiatry. 2024 Nov 18;15:1508732. doi: 10.3389/fpsyt.2024.1508732. eCollection 2024.
7
Psychosocial and personal predisposing factors of frostbite injury and associated amputation: a systematic review.
Inj Epidemiol. 2024 Nov 7;11(1):62. doi: 10.1186/s40621-024-00546-w.
8
Examining Lurasidone Efficacy in Patients with Schizophrenia Spectrum Illness and Concurrent Alcohol and Substance Use Disorder: A Prospective, Multicentric, Real-World Investigation.
J Clin Med. 2024 Apr 11;13(8):2206. doi: 10.3390/jcm13082206.
本文引用的文献
1
Navigating Evidence, Challenges, and Caution in the Treatment of Stimulant Use Disorders.
Brain Sci. 2023 Oct 6;13(10):1416. doi: 10.3390/brainsci13101416.
2
Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
CMAJ. 2023 Oct 16;195(40):E1364-E1379. doi: 10.1503/cmaj.230715.
3
Treatment outcomes in major depressive disorder in patients with comorbid alcohol use disorder: A STAR*D analysis.
J Affect Disord. 2023 Oct 15;339:691-697. doi: 10.1016/j.jad.2023.07.049. Epub 2023 Jul 17.
4
Meta-review on the efficacy of psychological therapies for the treatment of substance use disorders.
Psychiatry Res. 2023 Aug;326:115318. doi: 10.1016/j.psychres.2023.115318. Epub 2023 Jun 19.
5
Challenges of Treating ADHD with Comorbid Substance Use Disorder: Considerations for the Clinician.
J Clin Med. 2023 Apr 24;12(9):3096. doi: 10.3390/jcm12093096.
6
Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysis.
CNS Drugs. 2023 May;37(5):381-397. doi: 10.1007/s40263-023-01005-8. Epub 2023 May 11.
7
Efficacy of Cognitive Behavioral Therapy for Alcohol and Other Drug Use Disorders: Is a One-Size-Fits-All Approach Appropriate?
Subst Abuse Rehabil. 2023 Feb 19;14:1-11. doi: 10.2147/SAR.S362864. eCollection 2023.
8
Prevalence of Dual Diagnoses among Children and Adolescents with Mental Health Conditions.
Children (Basel). 2023 Feb 2;10(2):293. doi: 10.3390/children10020293.
9
Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis.
J Psychopharmacol. 2023 Feb;37(2):135-143. doi: 10.1177/02698811221142575. Epub 2022 Dec 12.
10
Psychiatric diagnosis and treatment in the 21st century: paradigm shifts versus incremental integration.
World Psychiatry. 2022 Oct;21(3):393-414. doi: 10.1002/wps.20998.
Zotero 插件